1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 13,715 | -0,11 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,742 | +1,09 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
| CENTOGENE | 0,169 | +141,43 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,512 | -1,88 % | Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role | ||
| BIOMERIEUX | 99,10 | +0,20 % | QVance AB Announces Nordic Partnership with bioMérieux | ||
| CYCLACEL | 0,346 | 0,00 % | Cyclacel-Aktie stürzt auf 52-Wochen-Tief von 0,32 US-Dollar | ||
| SYROS PHARMACEUTICALS | 0,270 | -3,57 % | Rechtsvorstand von Syros Pharmaceuticals verkauft Aktien im Wert von 10.320 US-Dollar | ||
| ANAPTYSBIO | 21,400 | 0,00 % | AnaptysBio, Inc.: Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update | Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis... ► Artikel lesen | |
| GENUS | 19,600 | -2,97 % | Genus Plc Expects FY25 Group Adj Profit Before Tax To Be In-line With Market View | LONDON (dpa-AFX) - Global animal genetics company Genus (GNS.L), on Tuesday, issued a trading update for the four months ending 31 October 2024 and said the Board expects Group adjusted profit... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,610 | +3,21 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ABIONYX PHARMA | 1,176 | -3,45 % | ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024 | Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma's CIR (€610k) as of September 30, 2024 Live broadcast of the General... ► Artikel lesen | |
| MEIRAGTX | 5,650 | 0,00 % | MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results | - Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 8,900 | -0,56 % | Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab | HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,243 | -10,17 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen |
ISR IMMUNE SYSTEM REGULATION HOLDING AB gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.
